The FDA faces legal challenges over GLP-1 shortages amid disputes between Eli Lilly and compounding pharmacists. FDA's flexibility and legal constraints in enforcing compounder regulations, and Lilly's responses, are under scrutiny. FDA advisory panel recommends a rare drug for approval despite efficacy concerns.